ATP2A3 (ATPase Sarcoplasmic/Endoplasmic Reticulum Ca²⁺ Transporting 3, also known as SERCA3) is a calcium pump encoded by the ATP2A3 gene located on chromosome 7p13. This protein is a member of the P-type ATPase family and plays a specialized role in intracellular calcium homeostasis. SERCA3 is increasingly recognized for its involvement in neurodegenerative diseases, particularly Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
The ATP2A3 gene encodes multiple isoforms through alternative splicing, with the full-length protein comprising approximately 1042 amino acids[1]. SERCA3 belongs to the SERCA family (SERCA1-3) and possesses the characteristic P-type ATPase structure:
SERCA3 pumps calcium from the cytosol into the endoplasmic reticulum (ER) lumen, playing a critical role in maintaining intracellular calcium homeostasis[1:1][2]:
SERCA3 regulates numerous cellular processes[2:1]:
SERCA3 has distinct tissue distribution:
SERCA3 dysfunction is implicated in AD pathogenesis through multiple mechanisms[3][4]:
ER calcium dysregulation: AD is characterized by ER calcium store depletion. SERCA3 impairment exacerbates this deficit, contributing to synaptic dysfunction and neuronal death[3:1].
Amyloid-beta toxicity: Aβ oligomers directly impair SERCA function, leading to calcium homeostasis disruption[4:1].
Synaptic plasticity: Impaired SERCA3 affects calcium-dependent synaptic plasticity mechanisms crucial for learning and memory[3:2].
Cellular stress: Chronic calcium dysregulation activates apoptotic pathways[4:2].
In Parkinson's disease, SERCA3 involvement includes[5]:
Dopaminergic neuron vulnerability: SERCA3 is highly expressed in dopaminergic neurons; dysfunction contributes to their selective vulnerability[5:1].
Alpha-synuclein toxicity: Alpha-synuclein aggregation disrupts ER calcium handling via SERCA3[5:2].
Mitochondrial dysfunction: SERCA3 impairment affects mitochondrial calcium buffering[5:3].
In ALS, SERCA3 plays a role in motor neuron pathology[6]:
ER stress: Motor neurons are particularly dependent on ER calcium homeostasis; SERCA3 dysfunction contributes to ER stress[6:1].
Excitotoxicity: Calcium dysregulation through SERCA3 affects glutamate excitotoxicity[6:2].
Protein aggregation: Impaired calcium handling affects protein quality control mechanisms[6:3].
In the central nervous system, SERCA3 is expressed in[3:3][5:4]:
Expression is modulated by neuronal activity and pathological states.
Targeting SERCA3 represents a therapeutic strategy for neurodegenerative diseases[7]:
Calcium homeostasis modulators: Drugs that enhance SERCA function (e.g., CDN1163) are in development[7:1].
ER stress reducers: Compounds that restore ER calcium balance are being investigated[7:2].
Gene therapy: AAV-mediated SERCA3 overexpression is under exploration[7:3].
ATP2A3 (SERCA3) is an ER calcium pump critical for intracellular calcium homeostasis. Its dysfunction contributes to neurodegeneration through ER calcium depletion, synaptic impairment, and activation of apoptotic pathways. Targeting SERCA3 function represents a promising therapeutic approach for AD, PD, and ALS. Understanding the isoform-specific roles of SERCA proteins in neurodegeneration continues to be an active area of research.
Bublitz, M., et al. (2018). The sarco(endo)plasmic reticulum Ca²⁺-ATPase (SERCA) family: an overview. Cold Spring Harbor Perspectives in Biology. 2018. ↩︎ ↩︎
Brini, M., & Carafoli, E. (2009). Calcium pumps in health and disease. Physiological Reviews. 2009. ↩︎ ↩︎
Sepulveda, F.J., et al. (2010). Synaptic dysfunction in Alzheimer's disease: calcium homeostasis and ER stress. Journal of Alzheimer's Disease. 2010. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Costa, R.O., et al. (2020). ER calcium dysregulation in Alzheimer's disease. Cell Calcium. 2020. ↩︎ ↩︎ ↩︎ ↩︎
Zündorf, G., & Reiser, G. (2011). Calcium dysregulation and apoptosis in neurodegenerative disease. Experimental Neurology. 2011. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Saxena, S., & Caroni, P. (2011). Selective neuronal vulnerability in neurodegenerative diseases. Neuron. 2011. ↩︎ ↩︎ ↩︎ ↩︎
Khanna, R., et al. (2020). Targeting calcium homeostasis in neurodegenerative diseases. Trends in Pharmacological Sciences. 2020. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Liu, X., et al. (2019). Association between ATP2A3 polymorphisms and Parkinson's disease. Neurobiology of Aging. 2019. ↩︎